ylliX - Online Advertising Network
Company Ticker News

Moderna’s stock gains 3% as it moves forward with Phase 3 clinical trial for RSV vaccine candidate

Moderna's stock gains 3% as it moves forward with Phase 3 clinical trial for RSV vaccine candidate

<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>

Shares of Moderna Inc. MRNA, +2.82% gained 3.0% in trading on Monday after the company said it began a Phase 3 clinical trial evaluating its respiratory syncytial virus vaccine candidate. RSV is a common, seasonal respiratory virus that causes cold symptoms; it is more likely to become serious in children and older adults.

...read full article on Market Watch

ylliX - Online Advertising Network